Deep Science Ventures and AbbVie to create companies to target inflammatory diseases
Deep Science Ventures (DSV), a London-based venture creator, is teaming up with AbbVie, a global…
November 28, 2022 - 2 minutes
Inflammatory disease
Triastek cleared for 3D printed medicine treatment of ulcerative colitis
Triastek, Inc. has received clearance for its Investigational New Drug (IND) application from the United…
November 18, 2022 - 2 minutes
BioSenic’s autoimmune disease platform adapting to meet unmet medical needs
BioSenic’s systemic autoimmune disease platform, originally designed by Medsenic, is now developing controlled dosages and…
November 14, 2022 - 4 minutes
EpiEndo gets regulatory approval for first patient study of first non-antibiotic macrolide
EpiEndo Pharmaceuticals, a clinical-stage biopharma company developing therapeutics for chronic inflammatory diseases, has received regulatory…
November 14, 2022 - 3 minutes
Researchers develop new nanoparticle to deliver drugs direct to macrophages
How can a drug be delivered exactly where it is needed, while limiting the risk…
November 10, 2022 - 4 minutes
Lipum starts chronic inflammatory disease drug study
Lipum AB (publ) says its phase 1 clinical study with the drug candidate SOL-116 has…
November 8, 2022 - 2 minutes
Delayed release tablets to treat ulcerative colitis launched in Canada
With Canada having one of the highest incidences of ulcerative colitis in the world, the…
October 25, 2022 - 2 minutes
C4XD and HitGen to collaborate on inflammation hit identification project
Drug discovery company C4X Discovery Holdings plc and HitGen Inc., which develops DNA-encoded library (DEL)…
October 20, 2022 - 2 minutes
NodThera reveals positive results for inflammasome inhibitors
Biotech company NodThera has announced positive phase 1 clinical readouts for its first and second…
September 21, 2022 - 2 minutes
Domainex’ drug shows positive data for treatment of interferonopathies
Interferonapathies such as lupus, Sjögren’s syndrome, and scleroderma could be treated effectively after positive human…
September 16, 2022 - 2 minutes
Arcutis Biotherapeutics acquires Ducentis BioTherapeutics in deal worth up to $400M
Arcutis Biotherapeutics, Inc. has entered into an agreement to acquire Ducentis BioTherapeutics Ltd., a privately…
September 8, 2022 - 4 minutes
Abivax pulls in €49.2M but needs more to complete ulcerative colitis program
French biotech company Abivax has completed an oversubscribed €49.2 million ($49 million) financing round. This…
September 2, 2022 - 4 minutes
